Name: Automated Antimicrobial Susceptibility Testing Market Size and Trends
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Automated Antimicrobial Susceptibility Testing Market, By Product Type (Consumables and Instruments), By Detection Method (Turbidimetric and Colorimetric), By Application (Antibacterial (Tuberculosis and Sepsis), Antifungal, Anti-parasitic, and Anti-viral), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Pathology/Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Published In : May 2019

Code : CMI2622

Pages :200

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Automated Antimicrobial Susceptibility Testing MarketSize and Trends

Automated Antimicrobial Susceptibility Testing Market – Insights

Automated antimicrobial susceptibility testing is extensively used to achieve minimum inhibitory concentration (MIC) results using an antimicrobial susceptibility testing system, which offers flexible, customizable testing options to accommodate laboratories of all sizes. Antimicrobial susceptibility testing (AST) aims to ensure that suitable antibiotics are prescribed to individuals by monitoring inhibition zone of antibiotics and emergence of resistant pathogens in infected individuals. Information on local patterns of antimicrobial susceptibility can be collected using antimicrobial susceptibility testing, so that policies guiding the therapy can be based on current data on local resistance trends or institutional antibiogram.

The global automated antimicrobial susceptibility testing market size was valued at US$ 1,295.5 million in 2018 and is expected to witness a CAGR of 8.9% over the forecast period (2018 – 2026).

Global Automated Antimicrobial Susceptibility Testing Market Share (%) Analysis, By Product Type, 2018

Source: Coherent Market Insights Analysis (2019)

Emergence of multidrug resistance worldwide is expected to drive growth of the automated antimicrobial susceptibility testing market

Increasing number of multidrug resistance cases in tuberculosis (TB), malaria, HIV, influenza, and others among the global population is expected to result in increasing adoption of antimicrobial susceptibility testing to reduce the resistance exposure during the forecast period. For instance, according to the World Health Organization (WHO), in 2014, there were around 480,000 new cases of multidrug-resistant tuberculosis (MDR-TB), a form of tuberculosis that is resistant to the two most powerful anti-TB drugs. Among these, only around 123,000 cases were detected and reported.

Moreover, increasing number of product launches is also expected to highly contribute to the automated antimicrobial susceptibility testing market growth. For instance, in March 2016, Becton, Dickinson and Company launched the new BD Phoenix M50 ID/AST system, which helps to deliver the same rapid, accurate, and cost-effective testing as the legacy BD Phoenix 100, within a small footprint.

Global Automated Antimicrobial Susceptibility Testing Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2026